Archive | April, 2013

Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product Delzicol

We know that, Mesalazine , also known as mesalamine (USAN) or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammatory bowel disease, such as ulcerative colitis and mild-to-moderate Crohn’s disease. Mesalazine is a bowel-specificaminosalicylate drug that acts locally in the gut and has its predominant actions there, thereby having few systemic side effects. As a derivative of salicylic acid, mesalazine is also thought to be an antioxidant that traps free radicals, which […]

Continue Reading

Getting the garlic blues

Pickler Andrew Dalby responded to one of my recent tweets about not cooking asparagus in lemon juice because it discolours it. He had found that his garlic cloves turned blue when he pickled them in spiced malt vinegar. The discolouration doesn’t mean that the pickles are inedible. Now plant material turning blue in acid (vinegar […]

Continue Reading

Positive results from Affinium Pharmaceuticals’ Phase 2a clinical trial of AFN-1252 in ABSSSI

We know that, AFN-1252, is a selective inhibitor of Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI), which is involved in fatty acid biosynthesis.  Now, Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252   in acute bacterial skin & skin structure infections (ABSSSI) demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for […]

Continue Reading

The Daily Fail

Periodically I receive links to stories in the British “tabloid” newspaper, The Daily Mail, from Sciencebase readers. I am yet to see anything in that paper that is worth the ink or electrons. Moreover, I wouldn’t even deem it fit to be torn up into squares and hung from a string in the lavatory for […]

Continue Reading

New Journal of Commercial Biotechnology issue

Journal of Commercial Biotechnology Vol 19, Issue 2 (2013) Capturing Value G. Steven Burrill Today‚Äôs pressure on pharmaceutical companies reflects greater pressures throughout the entire healthcare ecosystem as payers, patients, and providers wrestle with escalating costs and drive healthcare systems around the world away from being cost-based to becoming value-based. For pharmaceutical companies, this means […]

Continue Reading